Literature DB >> 19664906

Roles for cathepsins S, L, and B in insulitis and diabetes in the NOD mouse.

Lianne C Hsing1, Elizabeth A Kirk, Timothy S McMillen, Shuo-Hung Hsiao, Mark Caldwell, Barbara Houston, Alexander Y Rudensky, Renee C LeBoeuf.   

Abstract

We developed a panel of non-obese diabetic (NOD) mice deficient in major lysosomal cysteine proteases (cathepsins S, L and B) to identify protease enzymes essential for autoimmune diabetes. Null alleles for cathepsins (Cts) S, L or B were introgressed onto the NOD genetic background with 19 Idd markers at homozygosity. Diabetes onset was determined among females aged up to 6 months. We evaluated insulitis and sialadenitis in tissues using histology and computer assisted morphology. NOD mice deficient in Ctss or Ctsb were partially protected from diabetes with incidence at 33% and 28%, respectively, versus wild-type NOD (69%; p < 0.00001). NODs lacking cathepsin L (Ctsl-/-) are completely protected from IDDM, as originally shown by others. Ctsl, Ctss, or Ctsb heterozygous mice were able to develop IDDM, although incidence levels were significantly lower for Ctsb+/- (50%) and Ctsl+/- (55%) as compared to NODs (69%; p < 0.03). Ctsl-/- mice contain functional, diabetogenic T cells and an enriched Foxp3+ regulatory T cell population, and diabetes resistance was due to the presence of an expanded population of regulatory T cells. These data provide additional information about the potency of the diabetogenic T cell population in Ctsl-/- mice which were comparable in potency to wild-type NOD mice. These data illustrate the critical contribution of each of these proteases in determining IDDM in the NOD mouse and provide a useful set of models for further studies. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19664906      PMCID: PMC2822044          DOI: 10.1016/j.jaut.2009.07.003

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  31 in total

1.  Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling.

Authors:  W Roth; J Deussing; V A Botchkarev; M Pauly-Evers; P Saftig; A Hafner; P Schmidt; W Schmahl; J Scherer; I Anton-Lamprecht; K Von Figura; R Paus; C Peters
Journal:  FASEB J       Date:  2000-10       Impact factor: 5.191

Review 2.  Lysosomal cysteine proteases regulate antigen presentation.

Authors:  Karen Honey; Alexander Y Rudensky
Journal:  Nat Rev Immunol       Date:  2003-06       Impact factor: 53.106

3.  Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis.

Authors:  W Halangk; M M Lerch; B Brandt-Nedelev; W Roth; M Ruthenbuerger; T Reinheckel; W Domschke; H Lippert; C Peters; J Deussing
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

4.  Increased expression of GPI-specific phospholipase D in mouse models of type 1 diabetes.

Authors:  M A Deeg; R F Bowen; M D Williams; L K Olson; E A Kirk; R C LeBoeuf
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-07       Impact factor: 4.310

Review 5.  Emerging role of cathepsin S in obesity and its associated diseases.

Authors:  Soraya Taleb; Karine Clément
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

6.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

Authors:  B Salomon; D J Lenschow; L Rhee; N Ashourian; B Singh; A Sharpe; J A Bluestone
Journal:  Immunity       Date:  2000-04       Impact factor: 31.745

7.  Tissue inhibitor of metalloproteinase-2 inhibits T-cell infiltration and preserves pancreatic beta-cell function in an in vitro type 1 diabetes mellitus model.

Authors:  Chris C Woods; Krishnan Sundar; Cynthia Tessler; Ty W Lebsack; Lora Grainger; Alma Nielsen; David Bleich; Dominick DeLuca
Journal:  J Autoimmun       Date:  2006-06-09       Impact factor: 7.094

8.  Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c.

Authors:  M E Guicciardi; J Deussing; H Miyoshi; S F Bronk; P A Svingen; C Peters; S H Kaufmann; G J Gores
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

9.  Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis.

Authors:  Sajani S Lakka; Christopher S Gondi; Niranjan Yanamandra; William C Olivero; Dzung H Dinh; Meena Gujrati; Jasti S Rao
Journal:  Oncogene       Date:  2004-06-10       Impact factor: 9.867

10.  Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice.

Authors:  Galina K Sukhova; Yaou Zhang; Jie-Hong Pan; Youichiro Wada; Takashi Yamamoto; Makoto Naito; Tatsuhiko Kodama; Sotirios Tsimikas; Joseph L Witztum; Michael L Lu; Yasuhiko Sakara; Michael T Chin; Peter Libby; Guo-Ping Shi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

View more
  29 in total

1.  Enhanced anti-serpin antibody activity inhibits autoimmune inflammation in type 1 diabetes.

Authors:  Jan Czyzyk; Octavian Henegariu; Paula Preston-Hurlburt; Raman Baldzizhar; Christine Fedorchuk; Enric Esplugues; Kim Bottomly; Frans K Gorus; Kevan Herold; Richard A Flavell
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

Review 2.  De-coding genetic risk variants in type 1 diabetes.

Authors:  Melanie R Shapiro; Puchong Thirawatananond; Leeana Peters; Robert C Sharp; Similoluwa Ogundare; Amanda L Posgai; Daniel J Perry; Todd M Brusko
Journal:  Immunol Cell Biol       Date:  2021-02-24       Impact factor: 5.126

3.  CTSH regulates β-cell function and disease progression in newly diagnosed type 1 diabetes patients.

Authors:  Tina Fløyel; Caroline Brorsson; Lotte B Nielsen; Michela Miani; Claus Heiner Bang-Berthelsen; Martin Friedrichsen; Anne Julie Overgaard; Lukas A Berchtold; Anna Wiberg; Pernille Poulsen; Lars Hansen; Silke Rosinger; Bernhard O Boehm; Ramesh Ram; Quang Nguyen; Munish Mehta; Grant Morahan; Patrick Concannon; Regine Bergholdt; Jens H Nielsen; Thomas Reinheckel; Matthias von Herrath; Allan Vaag; Decio Laks Eizirik; Henrik B Mortensen; Joachim Størling; Flemming Pociot
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

Review 4.  Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.

Authors:  Pilar Brito-Zerón; Soledad Retamozo; Hoda Gheitasi; Manuel Ramos-Casals
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

5.  Cathepsin B regulates the appearance and severity of mercury-induced inflammation and autoimmunity.

Authors:  Christopher B Toomey; David M Cauvi; John C Hamel; Andrea E Ramirez; K Michael Pollard
Journal:  Toxicol Sci       Date:  2014-09-18       Impact factor: 4.849

6.  Cellular proliferation in mouse and human pancreatic islets is regulated by serpin B13 inhibition and downstream targeting of E-cadherin by cathepsin L.

Authors:  Chi-Wen Lo; Yury Kryvalap; Tzong-Jen Sheu; Ching-Ho Chang; Jan Czyzyk
Journal:  Diabetologia       Date:  2019-03-01       Impact factor: 10.122

Review 7.  Intracellular nucleic acid sensors and autoimmunity.

Authors:  Argyrios N Theofilopoulos; Dwight H Kono; Bruce Beutler; Roberto Baccala
Journal:  J Interferon Cytokine Res       Date:  2011-10-27       Impact factor: 2.607

8.  Downregulation of cathepsin G reduces the activation of CD4+ T cells in murine autoimmune diabetes.

Authors:  Fang Zou; Xiaoyang Lai; Jing Li; Shuihong Lei; Lei Hu
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 9.  Food safety.

Authors:  Andrea Borchers; Suzanne S Teuber; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2010-10       Impact factor: 8.667

10.  Anti-serpin antibody-mediated regulation of proteases in autoimmune diabetes.

Authors:  Raman Baldzizhar; Christine Fedorchuk; Mithilesh Jha; Chozhavendan Rathinam; Octavian Henegariu; Jan Czyzyk
Journal:  J Biol Chem       Date:  2012-11-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.